Identification of ligands that target the HCV-E2 binding site on CD81

Reem Al Olaby, Hassan M. Azzazy, Rodney Harris, Brett Chromy, Jost Vielmetter, Rod Balhorn

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatitis C is a global health problem. While many drug companies have active R&D efforts to develop new drugs for treating Hepatitis C virus (HCV), most target the viral enzymes. The HCV glycoprotein E2 has been shown to play an essential role in hepatocyte invasion by binding to CD81 and other cell surface receptors. This paper describes the use of AutoDock to identify ligand binding sites on the large extracellular loop of the open conformation of CD81 and to perform virtual screening runs to identify sets of small molecule ligands predicted to bind to two of these sites. The best sites selected by AutoLigand were located in regions identified by mutational studies to be the site of E2 binding. Thirty-six ligands predicted by AutoDock to bind to these sites were subsequently tested experimentally to determine if they bound to CD81-LEL. Binding assays conducted using surface Plasmon resonance revealed that 26 out of 36 (72 %) of the ligands bound in vitro to the recombinant CD81-LEL protein. Competition experiments performed using dual polarization interferometry showed that one of the ligands predicted to bind to the large cleft between the C and D helices was also effective in blocking E2 binding to CD81-LEL.

Original languageEnglish (US)
Pages (from-to)337-346
Number of pages10
JournalJournal of Computer-Aided Molecular Design
Volume27
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

hepatitis
Virus Attachment
viruses
Binding sites
Viruses
Hepacivirus
Binding Sites
Ligands
ligands
drugs
Interferometry
Glycoproteins
Surface Plasmon Resonance
Cell Surface Receptors
Surface plasmon resonance
Hepatitis C
Medical problems
surface plasmon resonance
Pharmaceutical Preparations
helices

Keywords

  • AutoDock
  • CD81 receptor
  • Dual polarization interferometry
  • HCV glycoprotein E2
  • Hepatitis C virus
  • Surface plasmon resonance
  • Viral entry inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Computer Science Applications

Cite this

Olaby, R. A., Azzazy, H. M., Harris, R., Chromy, B., Vielmetter, J., & Balhorn, R. (2013). Identification of ligands that target the HCV-E2 binding site on CD81. Journal of Computer-Aided Molecular Design, 27(4), 337-346. https://doi.org/10.1007/s10822-013-9649-3

Identification of ligands that target the HCV-E2 binding site on CD81. / Olaby, Reem Al; Azzazy, Hassan M.; Harris, Rodney; Chromy, Brett; Vielmetter, Jost; Balhorn, Rod.

In: Journal of Computer-Aided Molecular Design, Vol. 27, No. 4, 04.2013, p. 337-346.

Research output: Contribution to journalArticle

Olaby, RA, Azzazy, HM, Harris, R, Chromy, B, Vielmetter, J & Balhorn, R 2013, 'Identification of ligands that target the HCV-E2 binding site on CD81', Journal of Computer-Aided Molecular Design, vol. 27, no. 4, pp. 337-346. https://doi.org/10.1007/s10822-013-9649-3
Olaby, Reem Al ; Azzazy, Hassan M. ; Harris, Rodney ; Chromy, Brett ; Vielmetter, Jost ; Balhorn, Rod. / Identification of ligands that target the HCV-E2 binding site on CD81. In: Journal of Computer-Aided Molecular Design. 2013 ; Vol. 27, No. 4. pp. 337-346.
@article{2837f9842f364045bed6b34a129b6fd7,
title = "Identification of ligands that target the HCV-E2 binding site on CD81",
abstract = "Hepatitis C is a global health problem. While many drug companies have active R&D efforts to develop new drugs for treating Hepatitis C virus (HCV), most target the viral enzymes. The HCV glycoprotein E2 has been shown to play an essential role in hepatocyte invasion by binding to CD81 and other cell surface receptors. This paper describes the use of AutoDock to identify ligand binding sites on the large extracellular loop of the open conformation of CD81 and to perform virtual screening runs to identify sets of small molecule ligands predicted to bind to two of these sites. The best sites selected by AutoLigand were located in regions identified by mutational studies to be the site of E2 binding. Thirty-six ligands predicted by AutoDock to bind to these sites were subsequently tested experimentally to determine if they bound to CD81-LEL. Binding assays conducted using surface Plasmon resonance revealed that 26 out of 36 (72 {\%}) of the ligands bound in vitro to the recombinant CD81-LEL protein. Competition experiments performed using dual polarization interferometry showed that one of the ligands predicted to bind to the large cleft between the C and D helices was also effective in blocking E2 binding to CD81-LEL.",
keywords = "AutoDock, CD81 receptor, Dual polarization interferometry, HCV glycoprotein E2, Hepatitis C virus, Surface plasmon resonance, Viral entry inhibitors",
author = "Olaby, {Reem Al} and Azzazy, {Hassan M.} and Rodney Harris and Brett Chromy and Jost Vielmetter and Rod Balhorn",
year = "2013",
month = "4",
doi = "10.1007/s10822-013-9649-3",
language = "English (US)",
volume = "27",
pages = "337--346",
journal = "Journal of Computer-Aided Molecular Design",
issn = "0920-654X",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Identification of ligands that target the HCV-E2 binding site on CD81

AU - Olaby, Reem Al

AU - Azzazy, Hassan M.

AU - Harris, Rodney

AU - Chromy, Brett

AU - Vielmetter, Jost

AU - Balhorn, Rod

PY - 2013/4

Y1 - 2013/4

N2 - Hepatitis C is a global health problem. While many drug companies have active R&D efforts to develop new drugs for treating Hepatitis C virus (HCV), most target the viral enzymes. The HCV glycoprotein E2 has been shown to play an essential role in hepatocyte invasion by binding to CD81 and other cell surface receptors. This paper describes the use of AutoDock to identify ligand binding sites on the large extracellular loop of the open conformation of CD81 and to perform virtual screening runs to identify sets of small molecule ligands predicted to bind to two of these sites. The best sites selected by AutoLigand were located in regions identified by mutational studies to be the site of E2 binding. Thirty-six ligands predicted by AutoDock to bind to these sites were subsequently tested experimentally to determine if they bound to CD81-LEL. Binding assays conducted using surface Plasmon resonance revealed that 26 out of 36 (72 %) of the ligands bound in vitro to the recombinant CD81-LEL protein. Competition experiments performed using dual polarization interferometry showed that one of the ligands predicted to bind to the large cleft between the C and D helices was also effective in blocking E2 binding to CD81-LEL.

AB - Hepatitis C is a global health problem. While many drug companies have active R&D efforts to develop new drugs for treating Hepatitis C virus (HCV), most target the viral enzymes. The HCV glycoprotein E2 has been shown to play an essential role in hepatocyte invasion by binding to CD81 and other cell surface receptors. This paper describes the use of AutoDock to identify ligand binding sites on the large extracellular loop of the open conformation of CD81 and to perform virtual screening runs to identify sets of small molecule ligands predicted to bind to two of these sites. The best sites selected by AutoLigand were located in regions identified by mutational studies to be the site of E2 binding. Thirty-six ligands predicted by AutoDock to bind to these sites were subsequently tested experimentally to determine if they bound to CD81-LEL. Binding assays conducted using surface Plasmon resonance revealed that 26 out of 36 (72 %) of the ligands bound in vitro to the recombinant CD81-LEL protein. Competition experiments performed using dual polarization interferometry showed that one of the ligands predicted to bind to the large cleft between the C and D helices was also effective in blocking E2 binding to CD81-LEL.

KW - AutoDock

KW - CD81 receptor

KW - Dual polarization interferometry

KW - HCV glycoprotein E2

KW - Hepatitis C virus

KW - Surface plasmon resonance

KW - Viral entry inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84878496063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878496063&partnerID=8YFLogxK

U2 - 10.1007/s10822-013-9649-3

DO - 10.1007/s10822-013-9649-3

M3 - Article

C2 - 23612915

AN - SCOPUS:84878496063

VL - 27

SP - 337

EP - 346

JO - Journal of Computer-Aided Molecular Design

JF - Journal of Computer-Aided Molecular Design

SN - 0920-654X

IS - 4

ER -